NeuroVive Pharmaceutical AB—amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act
(1991:980), the company is hereby reporting that as a result of new share issues
conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by an
Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the
Board of Directors with the authorization of a shareholders’ meeting on 31
January 2014, the number of shares and votes of NeuroVive registered with the
Swedish Companies Registration Office have increased by 6,129,047. Accordingly,
the total number of shares and votes in NeuroVive is 27,788,093.
About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

For media and investor relations questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48,
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 31 March 2014, at 8:30 a.m. CET.